Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:RPRX

Royalty Pharma Q3 2026 Earnings Date & Estimates

Royalty Pharma logo
$56.21 -0.55 (-0.97%)
Closing price 10/8/2026 04:00 PM Eastern
Extended Trading
$56.65 +0.44 (+0.78%)
As of 08:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Royalty Pharma is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Royalty Pharma in Q3 2026

Royalty Pharma is expected to post earnings of $1.18 per share on revenue of $884.84 million. In the same quarter a year earlier Royalty Pharma reported $1.17 per share on revenue of $609.29 million. Royalty Pharma last reported on August 5, 2026, posting $1.32 per share and beating the $1.27 consensus estimate. Royalty Pharma has beaten the consensus EPS estimate in 8 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$1.18
Expected Revenue
$884.84 million
Prior-Year EPS
$1.17
Prior-Year Revenue
$609.29 million
Expected EPS Growth
+0.9%
Expected Revenue Growth
+45.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$1.32 (Beat by +$0.05)
Last Quarter Revenue
$674.14 million
EPS Beat Rate
8 of last 8 quarters

Prepare for the Q3 2026 Call

Royalty Pharma Q3 2026 Earnings FAQ

Royalty Pharma (NASDAQ:RPRX) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens.

Royalty Pharma's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Royalty Pharma to post earnings of $1.18 per share for Q3 2026.

The consensus revenue estimate for Royalty Pharma is $884.84 million for Q3 2026.

Royalty Pharma Earnings Headlines

Royalty Pharma (RPRX) Gets a Buy from Morgan Stanley
October 8 at 8:17 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/5072769/royalty-pharma-rprx-gets-a-buy-from-morgan-stanley/
Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run
September 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/royalty-pharma-rprx-stock-looks-111438993.html
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
October 9 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns
September 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/royalty-pharma-rprx-could-10-101607557.html
Royalty Pharma Plc (RPRX)
September 18, 2026  |  za.investing.comhttps://za.investing.com/equities/royalty-pharma-plc-news
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
September 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362675/0/en/royalty-pharma-announces-7-5-million-gift-to-blood-cancer-united-to-expand-therapy-acceleration-program.html
See More Royalty Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Royalty Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Royalty Pharma and other key companies, straight to your email.

About Royalty Pharma

Royalty Pharma (NASDAQ:RPRX) is a biopharmaceutical royalty acquisition company that provides funding to life sciences companies in exchange for rights to future payments associated with approved or development-stage medicines. Its business model gives biotechnology and pharmaceutical companies access to capital while allowing Royalty Pharma to participate in the commercial success of therapies without directly developing or marketing them.

The company invests in royalties and other economic interests tied to a broad range of biopharmaceutical products, including treatments for cancer, rare diseases, immune disorders, diabetes and other chronic conditions. Its portfolio has included royalty interests associated with marketed medicines as well as therapies undergoing clinical development, providing exposure across multiple stages of the drug-development cycle.

Royalty Pharma was founded in 1996 by Pablo Legorreta and has completed transactions with pharmaceutical and biotechnology companies, academic institutions and other life sciences organizations. The company serves a global market, with investments and royalty interests linked to products commercialized in multiple regions. Pablo Legorreta serves as Royalty Pharma’s founder and chief executive officer.

View Royalty Pharma Profile
Earnings Tools